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Abstract
Vasculitis (angiitis) is a systemic autoimmune disease that often causes fatal symptoms. We aimed to
isolate cDNA markers that would be useful for diagnosing not only vasculitis but also other autoimmune
diseases. For this purpose, we used stepwise subtractive hybridization and cDNA microarray analyses to
comprehensively isolate the genes whose expressions are augmented in peripheral blood mononuclear
cells (PBMCs) pooled from vasculitis patients. Subsequently, we used quantitative real-time polymerase
chain reaction (qRT–PCR) to examine the mRNA levels of each candidate gene in individual patients.
These analyses indicated that seven genes exhibit remarkably augmented expression in many vasculitis
patients. Of these genes, we analyzed G0/G1 switch gene 2 (G0S2) further because G0S2 expression is
also enhanced in the PBMCs of patients with systemic lupus erythematodes (SLE). We generated G0S2
transgenic mice that ubiquitously overexpress human G0S2. Although we did not observe any obvious
vasculitis-related histopathologic ﬁndings in these mice, these mice are unhealthy as they produce only
few offspring and showed elevated serum levels of two autoimmunity-related antibodies, anti-nuclear anti-
body, and anti-double strand DNA antibody. Thus, our large-scale gene proﬁling study may help ﬁnding
sensitive and speciﬁc DNA markers for diagnosing autoimmune diseases including vasculitis and SLE.
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1. Introduction
There are  10 different disorders that are classiﬁed
as vasculitis (also known as angiitis). Vasculitis is a
systemic autoimmune disease characterized by the
chronic inﬂammation of systemic blood vessels, veins,
and arteries of all types and sizes. This often causes
symptoms that can rapidly induce death, such as the
formation of blood clots (thrombosis), restriction of
oxygenated blood supply (ischemia), and irreversible
injury to affected organs.
1 Although immune system
disturbances appear to be the main cause of the
disease,thepathogenesisofvasculitisisnotfullyunder-
stood. The diagnosis and treatment of vasculitis was
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DNA RESEARCH 15, 253–265, (2008) doi:10.1093/dnares/dsn014recently greatly aided by the observation that three
vasculitis disorders, namely Wegener’s granulomatosis
(WG), microscopic polyangiitis (MPA), and Churg–
Strauss syndrome (CSS), are characterized by the
presence of circulating antineutrophil cytoplasmic
antibodies (ANCAs).
2,3 Two different types of ANCA
have been identiﬁed. C-ANCA targets proteinase-3
and is most frequently found in WG, whereas P-ANCA,
which targets myeloperoxidase, is most frequently
detected in MPA and CSS. Consequently, enzyme
immunosorbent assays (EIA) that examine the ability
of patient serum to bind to these enzymes can be
used to diagnose WG, MPA, and CSS. However, diag-
noses made on the basis of positive EIAs will still need
tobeconﬁrmedbybiopsies.Moreover,manyothervas-
culitis disorders are not characterized by the presence
of ANCAs. Thus, the diagnosis of vasculitis disorders
requires the identiﬁcation of more convenient and
generally applicable diagnostic markers. The identiﬁ-
cation of these markers may also provide insights into
the pathogenesis behind this disorder and improve
the therapy of vasculitis.
We have isolated putative gene markers that are
characteristic to the autoimmune diseases, such as
systemic lupus erythematodes (SLE)
4 and rheumatoid
arthritis (RA)
5, using peripheral blood mononuclear
cells (PBMCs). Here, we sought to identify new gene
markers that can distinguish the autoimmune
disease, in particular vasculitis, from other diseases
with high speciﬁcity when PBMCs serve as the
sample. For this purpose, we used the stepwise sub-
traction technique
6 and high-density oligonucleotide
microarrays to isolate those genes that show dramati-
cally upregulated expression commonly in the pooled
PBMC mRNAs of varieties of vasculitis patients regard-
less of the patient’s symptom, active, or inactive phase
when compared with normal volunteer PBMC
mRNAs. To identify the genes that are upregulated
in many vasculitis patients, we selected and mixed
the PBMC mRNAs from patients with one of the
following seven vasculitis disorders: WG, MPA,
Takayasu’s arteritis (TA), allergic granulomatous angii-
tis (AGA), malignant RA (MRA ¼ rheumatoid vas-
culitis), giant cell arteritis (GCA), and polyarteritis
nodosa (PN). We found that the following seven
genes are commonly unpregulated in the PBMCs of
many of these vasculitis patients regardless of their
symptoms: early growth response 1 (EGR1), G0/G1
switch gene 2 (G0S2), hemoglobin delta (HBD),
amphiregulin (also known as AREG), interleukin-1
receptor type II (IL1R2), calgranulin C, and a novel
gene named TVAS10. Of these genes, we selected
G0S2 for further analysis because its physiological
functions are poorly understood. We prepared anti-
G0S2 antibodies and then generated G0S2 transgenic
mice and examined their phenotype. We propose that
the vasculitis gene markers we identiﬁed here may be
useful for the future diagnosis of vasculitis.
2. Materials and methods
2.1. Human subjects and ethical considerations
All systemic vasculitis patients used in this study
were diagnosed according to a previously documen-
ted proposal (the ACR criteria and the CHCC cri-
teria).
1 This study was reviewed and approved by
the Internal Review Board of the Research Institute
for Microbial Diseases, Osaka University. Accordingly,
written informed consent was obtained from all par-
ticipants before their PBMCs were obtained. Serum
samples were consecutively obtained regardless of
the patient’s symptom, active, or inactive phase.
2.2. Statistical analysis
Signiﬁcant differences were determined by using
Mann–Whitney U-test (Figs. 1 and 2B, Supplementary
Fig. S1). The data are expressed as means+SE. P-value
of ,0.05 or ,0.01 was considered to be statistically
signiﬁcant.
2.3. Transgene vector construction and production of
G0S2 transgenic mice
To construct the transgene vector pCX-G0S2, the
human G0S2 ORF was cloned from a SLE cDNA
library
4 by PCR with the EcoRI site-bearing primers
G0S2-EcoRI-5’F (5’-TATGAATTCGCCACCATGGAAACGG
TCCAGGAGCTGATC-3’) and G0S2-EcoRI-3’R (5’-ATA
GAATTCCTAGGAGGCGTGCTGCCGGTTGGAC-3’). The
G0S2-EcoRI-5’F primer contains the Kozak sequence
ahead of the start codon of G0S2 cDNA, whereas
the G0S2-EcoRI-3’R primer contains the stop codon
of G0S2 cDNA. The sequence of the ampliﬁed
product was conﬁrmed by DNA sequencing. As pre-
viously described,
7 the EcoRI-digested fragment of
the ampliﬁed G0S2 ORF was inserted into the EcoRI
site of the pCAGGS expression vector, which possesses
a chicken b-actin promoter and a cytomegalovirus
enhancer (CMV-IE enhancer). The resulting construct
was designated pCX-G0S2. To prepare the G0S2 frag-
ment bearing the chicken b-actin promoter and the
CMV-IE enhancer for injection into fertilized eggs,
the SalI/HindIII fragment of pCX-G0S2 was puriﬁed
by electrophoresis and agarose gel extraction. The
G0S2 transgenic embryos and mice were generated
according to previously described protocols.
7 Brieﬂy,
the puriﬁed DNA fragments were injected into
B6D2F1  B6D2F1 fertilized eggs. The incorporation
of the transgene was examined by the genomic PCR
analysis using DNA extracted from the tail and
the pCX-G0S2-1685F (5’-GCTGGTTGTTGTGCTG
TCTCATCA-3’) and pCX-G0S2-2161R (5’-GCCAG
254 Asculitis-upregulated Genes [Vol. 15,AAGTCAGATGCTCAAGGGGCTTCA-3’) primers. The
PCR conditions involved TaKaRa Ex Taq polymerase
(Takara, Shiga, Japan) and a pre-heating step (958C
for 2 min), 30 reaction step cycles (958C for 30 s,
588C for 30 s, 728C for 1 min), and a ﬁnal elongation
step (728C for 5 min). The founder mice were mated
with C57BL/6 mice and both the transmittance of
the transgene and the successful expression of
human G0S2 protein were examined by western
blot analysis of total cell extracts of mouse tails
using one of the anti-G0S2 monoclonal antibodies
(clone #3-1) we generated (see section 3.4 and
Supplementary Fig. S2).
2.4. Histological examination
C57BL/6 mice were purchased from Japan SLC
(Hamamatsu,Japan).Mousetissueswere ﬁxed immedi-
ately after removal with 4% paraformaldehyde, then
embedded in parafﬁn, and cut into sections (4 mm
Figure 1. mRNA expression of selected TAS/TAC genes in the PBMCs from individual vasculitis patients and normal volunteers. qRT–PCR
analyses show that (A) EGR1 (TAC-1), (B) G0S2 (TAC-40), (C) HBD (TAC-106), (D) Amphiregulin (TAC-9), and (E) TVAS10 (TAC-30)a r e
generally upregulated in the PBMCs of vasculitis patient (circles) but not in the PBMCs of normal volunteers (triangles). Each symbol
denotes the mean value of a sample analyzed in triplicate. The leftmost ﬁlled circle signiﬁes an RNA sample from the PBMCs of a
healthy volunteer (male, age 52), which was used as a standard sample and whose expression level was set to 1.0. It allowed us to
compare all of the expression proﬁles tested in this study. Average+SE values of the vasculitis patient and normal volunteer groups
are shown in the right-hand graphs and differ signiﬁcantly (P, 0.01).
No. 4] S. Kobayashi et al. 255thick).Somesectionswere stainedwithhematoxilnand
eosinaccordingtostandardprocedures, whereas others
were stained with the clone #3-1 monoclonal anti-
G0S2 antibody according to the previously described
procedure.
8 To evaluate the immunostain, sections of
the same organs from G0S2-TG and C57BL/6 mice
were processed at the same time. When the immuno-
reactivesignalsintheformersectionsweresubstantially
strongerthanthoseinthelatter,theywereconsideredto
indicate theexogenicG0S2 proteins produced fromthe
transgene.
2.5. In situ hybridization
Sections were processed in the Genostaff laboratory
(Tokyo,Japan)byusingtheDIGRNAlabelinganddetec-
tion kits (Roche Diagnostics, Mannheim, Germany).
Brieﬂy, G0S2 antisense and sense (negative control)
RNA probes were prepared by in vitro transcription of
the pBluescript vector containing the full-length
human G0S2 cDNA according to the manufacturer’s
instructions. Hybridized signals were colored blue with
4-nitro blue tetrazolium chloride and 5-bromo-4-
chloro-3-indolyl-phosphate as a substrate of alkaline
phosphatase. The sense probe did not yield any
signiﬁcant stains. Further information concerning the
insituhybridization(ISH)methodisavailableonrequest.
2.6. Serologic examination
Approximately 200 ml of peripheral blood per
mouse were collected from the orbital plexus under
anesthesia and were left for 1 h to coagulate. After
centrifugation,  20 ml sera were obtained. The sera
were frozen at 2208C and sent to the Mitsubishi
Kagaku BCL laboratory (Tokyo, Japan), where each
serum was diluted 500 times and analyzed for the
levels of anti-nuclear and anti-double strand (ds)
DNA antibodies by ﬂuorescent antibody tests or
enzyme immunoassays.
3. Results
3.1. Identiﬁcation of vasculitis-speciﬁc genes by
stepwise subtraction and DNA microarray
analysis
To isolate the putative vasculitis-speciﬁc genes that
are commonly upregulated in the PBMCs of vasculitis
patients,we ﬁrst used our stepwisesubtractive hybridiz-
ationmethod.PBMCsampleswereobtainedfromvascu-
litis patients (50 patients in total) regardless of the
patient’s symptom, active, or inactive phase, and a
cDNA library was prepared from their pooled mRNAs
by the linker-primer method using a pAP3neo vector.
9
Stepwise subtractive hybridization was then performed
using the biotinylated pooled mRNAs from the PBMCs
of eight normal volunteers, as described previously.
6
This generated a library of genes that are upregulated
in only vasculitis PBMCs. To examine whether these
genes are actually upregulated in vasculitis but not
normal PBMCs, we performed northern blot analysis
using the pooled mRNAs from the vasculitis and
normal PBMCs (Fig. 3A). For the cDNA clones whose
expressionlevelsweretoolow fordetectionbynorthern
blot analysis, we examined their expression in vasculitis
and normal PBMCs by RT–PCR (Fig. 3B). The 29 genes
that were conﬁrmed to be upregulated in vasculitis
patients were called TAS after transcript augmented in
vasculitis isolated by stepwise-subtraction. The TAS
genes and their accession numbers are summarized in
Table 1.
To increase the number of putative vasculitis-
speciﬁc genes, we also performed a genome-wide
complementary DNA microarray analysis using the
Agilent Hu44K array with the same pooled vasculitis
and normal PBMC RNA samples. When we tested
the top 402 genes from the microarray list of vasculi-
tis-upregulated genes (data not shown) by RT–PCR,
we identiﬁed 63 genes whose expression levels are
dramatically upregulated in vasculitis patient PBMCs
Figure 2. Family tree of G0S2 transgenic mice. (A) Of the 61 mice
tested in the ﬁrst trial, six G0S2 transgenic mouse lines were
generated. They all died except for the GTG1b line, which was
not useful for further analysis because the human G0S2 gene
was introduced on the Y chromosome; consequently, this
mouse only produced male G0S2 transgenic mice. (B) Of the
22 mice tested in the third trial, three G0S2 transgenic mouse
lines were generated. The only surviving GTG3a line is now
under large scale propagation to establish a strain.
256 Asculitis-upregulated Genes [Vol. 15,(Fig. 4). We called them TAC after transcript augmen-
ted in vasculitis isolated by cDNA-microarray. The TAC
genes and their accession numbers are summarized in
Table 2. Dual speciﬁcity phosphatase 1 (DUSP1) and
IL1R2 were identiﬁed by both methods. Of the 92
TAS and TAC genes, 30 genes are uncharacterized
genes. These are designated as TVAS after transcript
increased in vasculitis.
3.2. Expression proﬁles of vasculitis-upregulated genes
in individual patients
To determine whether these vasculitis-speciﬁc can-
didate genes are indeed upregulated in patients suf-
fering from WG, MPA, TA, AGA, MRA, GCA, or PN and
thus are general markers of vasculitis, we subjected
25 of the TAS and TAC genes (underlined in Tables 1
and 2) to quantitative RT–PCR (qRT–PCR) using
PBMC RNA samples from indicated numbers of indi-
vidual vasculitis patients and normal volunteers as
negative controls (Fig. 1 and Supplementary Fig. S1).
In every qRT–PCR, a standard RNA (denoted as
normal with a relative intensity of 1.0) from the
PBMCs of a healthy volunteer (male, age 52) was
used (see the leftmost ﬁlled circle in Fig. 1A–E); this
allowed us to compare the expression proﬁles of the
genes tested in this study. It also allowed us to
compare the expression proﬁles of the genes in this
study with those of other genes tested in our previous
studies on SLE
4 and RA.
5 With this experiment, we
expected to isolate those genes that are highly
expressed not only in many vasculitis patients but
also in patients with SLE
4 and RA;
5 the identiﬁcation
of such marker genes may be useful as sensitive and
speciﬁc diagnostic tools.
Of the 25 TAS/TAC genes tested, TAC-1 [early growth
responses 1 (EGR1)] was one of the most strongly
upregulated genes commonly in the PBMCs of many
vasculitis patients, as 96% of patients expressed this
gene at 3–300-fold higher levels than healthy volun-
teers (Fig. 1A). EGR1 encodes a zinc ﬁnger transcription
factorwhoseexpressionisinducedwithinminutesupon
the reception of growth stimuli; its expression then
decays within a few hours. It promotes cellular differen-
tiationalongamacrophagelineage.
10Italsoplaysacriti-
cal role in the response to both acute and chronic
vascular stress by inducing the expression of several
geneproductslinkedtocellularperturbation.Thisispar-
ticularlytrueforthecellularperturbationinthevascula-
ture that is induced by hypoxia, ischemia/reperfusion,
atherosclerosis, and acute vascular injury.
11 It remains
unclear whether the induction of EGR1 in vasculitis is a
pathogenic response or merely results from vascular
stress. Nonetheless, EGR1 may serve as a gene marker
for the diagnosis of vasculitis.
TAC-40 (G0S2) is a lymphocyte G0/G1 switch gene
that encodes a putative cell cycle inhibitor whose
expression may be required before cells become com-
mitted to enter the G1 phase of the cell cycle.
12
Nearly, half of the vasculitis patients showed .20-
fold increased expression, whereas the expression of
most of the normal volunteers was much lower
(Fig. 1B). Notably, relative to healthy controls, G0S2
expression is also enhanced in the PBMCs from
patients with other autoimmune diseases, namely
SLE
4 and RA.
5 Microarray and qRT–PCR analyses also
showed that G0S2 is upregulated in the PBMCs from
psoriasis patients suffering from severe generalized
disease.
13 Thus, it may be interesting to analyze
G0S2 further, as it may shed light on the pathogenesis
of vasculitis at the molecular level (see below).
Nearly 77% of the vasculitis patients expressed
3–16-fold more TAC-106 (HBD) mRNA than the
normal volunteers (Fig. 1C). HBD is a minor type of
hemoglobin (it makes up only 2–3% of adult hemo-
globin) that forms a complex with a-hemoglobin
called hemoglobin A2 (a2d2).
14 Although high HbA2
levels are diagnostic for the b-thalassemia trait, its
relevance to vasculitis pathology is unknown.
Nonetheless, it may be useful as a diagnostic gene
marker for vasculitis.
Amphiregulin is one of the epidermal growth factor
(EGF)-like growth factors that stimulate cell growth by
activating the EGF receptor signaling of target cells in
an autocrine/juxtacrine fashion.15 We previously
reported that Amphiregulin expression is enhanced in
the PBMCs of some patients with SLE
4 and RA.
5
Figure 3. mRNA expression levels of the TAS genes. Individual TAS
genes were subjected to northern blot (A) or RT–PCR (B)
analysis to conﬁrm they are upregulated in the PBMCs of 50
vasculitis patients (A) but not in the PBMCs of eight normal
volunteers (N). Table 1 provides the names of the TAS genes.
GAPDH was also analyzed as a loading control. The annealing
temperature for RT–PCR was always 588C and ampliﬁcation
occurred over 30 cycles. The sequences of the primers used to
identify the TAS genes are presented in Supplementary Table S1.
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smaller proportion of vasculitis patients show
enhanced Amphiregulin expression (Fig. 1D). Thus,
Amphiregulin may be more signiﬁcant as a DNA
marker for SLE and RA than for vasculitis.
TAC30(¼TVAS10)encodesanuncharacterizednovel
protein that is composed primarily of an ankyrin
repeat, which is one of the most frequently observed
amino-acid motifs and is important for protein–
protein interactions.
16 About a half of the vasculitis
patients showed 10–200-fold increased expression of
TAC30, whereas healthy volunteers showed very low
expression except for one case (Fig. 1E).
Interleukin-1 (IL1), a principal macrophage-derived
cytokine, plays a pivotal role in the immuno-
inﬂammatory process by triggering cell activation via
itstypeI receptor (IL1R1); in contrast, itstype II receptor
(IL1R2) lacks the intracellular domain for IL1 signaling
and functions as a potent, speciﬁc, and natural inhibitor
of IL1 by acting as a decoy receptor.
17 About half of the
vasculitis patients showed 20–50-fold IL1R2 expression
(one patient showed  300-fold expression), whereas
healthy volunteers showed very low expression except
for one case (Supplementary Fig. S1A). This increased
expression of IL1R2 may be related to the vascular
inﬂammation of the vasculitis patients.
Three phagocyte-speciﬁc S100 proteins called
calgranulin- A, -B, and -C act separately during calcium-
dependent signaling. In particular, TAS1-191 (calgranu-
lin C) secretion by tumor necrosis factor (TNF)- stimu-
lated granulocytes causes target cell activation that
resultsintheupregulatedexpressionofproinﬂammatory
Table 1. List of stepwise subtraction identiﬁed TAS genes that show upregulated expression in vasculitis patient PBMCs
Gene name Accession number Sequence description
TAS1-120 AK091533 Unknown (sapiens cDNA FLJ34214) ¼ TVAS1
TAS1-126 NM_006013 Ribosomal protein L10 (RPL10)
TAS1-137 AC007318 Unknown (AL049356) ¼ TVAS2
TAS1-140 BC033089 Lipocalin 2 (oncogene 24p3)
TAS1-149 BC008684 Similar to splicing factor, arginine/serine-rich (MGC:9742)
TAS1-160 NM_016304 Unknown (C15orf15) ¼ TVAS3
TAS1-198 BC010878 ASF1 anti-silencing function 1 homolog A
TAS1-267 BC042436 Unknown (IMAGE:4471726) ¼ TVAS4
TAS1-377 AY275537 Unknown (isolate 183 mitochondrion) ¼ TVAS5
TAS2-047 BC047681 S100 calcium binding protein A9 (calgranulin B)
TAS2-078 NM_004417 Dual speciﬁcity phosphatase 1 (DUSP1)
TAS2-097 D89974 Glycosylphosphatidyl inositol-anchored protein GPI-80
TAS3-032 NM_015384 Nipped-B homolog (Drosophila) (NIPBL)
TAS3-039 NM_001030 Ribosomal protein S27 (metallopanstimulin 1) (RPS27)
TAS3-046 BC000927 Poly(A) polymerase alpha
TAS3-047 NM_000517 Hemoglobin, alpha 2 (HBA2)
TAS3-053 NM_004633 Interleukin 1 receptor, type II (IL1R2)(AY124010)
TAS3-062 BC000163 Vimentin
TAS3-076 BC064910 Beta-2-microglobulin
TAS3-079 BC001429 Annexin A5
TAS3-112 AY195792 Unknown (haplotype As9Y mitochondrion) ¼ TVAS6
TAS3-133 NM_005870 Sin3-associated polypeptide, 18kDa (SAP18)
TAS3-135 BC018183 NADH dehydrogenase (ubiquinone) 1 beta subcomplex
TAS4-011 CR611844 Unknown (CS0DL007YO12 of B cells) ¼ TVAS7
TAS1-171 AY260957 Insulin-like growth factor 1 (somatomedin C) (IGF1)
TAS1-191 NM_005621 S100 calcium-binding protein A12 (calgranulin C)
TAS1-272 NM_003805 CASP2 and RIPK1 domain containing adaptor with death domain (CRADD)
TAS1-274 NM_004592 Splicing factor, arginine/serine-rich 8 (SFRS8)
TAS1-301 BC062616 Protein serine kinase H1
The expression levels of the TAS genes were examined by northern blot (Fig. 1A) and/or RT–PCR (Fig. 1B). The underlined genes were sub-
jected to qRT–PCR to determine their generality of expression in vasculitis patients but not normal volunteers (Fig. 3).
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may thenstimulate granulocytestosecretemorecalgra-
nulin C, thereby establishing a self-amplifying positive
feedback loop.
18 About 30% of vasculitis patients
showed 10–50-fold calgranulin C expression (one
patient showed  150-fold expression), whereas most
of the healthy volunteers showed low expression
(Supplementary Fig. S1B). In contrast, the vasculitis
patients and normal volunteers did not differ in their
expressionofcalgranulinB(TAS2-047)(datanotshown).
3.3. Expression pattern of TAS/TAC genes in PBMC
We previously reported that G0S2 was primarily
expressed in monocytes, whereas Amphiregulin was
expressed in both monocytes, T cells and B cells by
performing RT–PCR on multiple-tissue cDNA panels
(MTC) from Clontech (Palo Alto, CA).
5 To determine
whether EGR1, HBD, TVAS10, IL1R2, and calgranulin
C are also expressed in particular human blood cells,
we conducted similar experiments. As shown in
Fig. 5, EGR1 and IL1R2 were expressed ubiquitously
in all lanes, albeit with varying intensities. cDNA
from placenta, which also contains many blood cells,
served as a control. All genes except calgranulin C
were strongly expressed in activated CD4
þ T cells
(lane 8) and weakly expressed in activated mono-
nuclear cells (aMNCs) (lane 7). Only EGR1 and
TVAS10 were expressed in activated CD8
þ T (lane 9)
cells. EGR1, TVAS10, IL1R2, and calgranulin C were
expressed in resting CD8
þ T cells (T-suppressor/
cytotoxic; lane 2) and monocytes (lane 4). These
observations together indicate that these vasculitis-
upregulated genes have similar expression proﬁles.
Unfortunately, we could not perform this analysis on
vasculitis patients because of the low numbers of
PBMCs that we could obtain from the patients.
3.4. Preparation of transgenic mice that overexpress
G0S2
We selected G0S2 for further analysis because little
is known about its physiological signiﬁcance and func-
tion. To explore the physiological signiﬁcance of G0S2,
we prepared transgenic mice that overexpress the
human gene for G0S2. For this purpose, we con-
structed plasmid DNA in which human G0S2 cDNA
lies directly downstream of the beta-actin promoter,
as described previously.
7 This construct was used to
generate transgenic mouse lines that express human
G0S2 protein in all tissues. The successful generation
of these transgenic mice was conﬁrmed by PCR and/
or western blot analysis using DNA or cell extracts
obtained from the tail. Expression of G0S2 protein
was conﬁrmed by the monoclonal antibody (#3-1)
we prepared here (see Supplementary Result and
Fig. S2). Although the transgenic mice did not
exhibit an obvious phenotype, they seemed to be
unhealthy as they did not produce large numbers of
offspring. This made it very difﬁcult to establish this
transgenic mouse line. For example, in the ﬁrst
attempt to generate this line, 61 mice were tested
by PCR for expression of human G0S2. Of these,
three female and three male mice were found to
bear the transgene (GTG1a-f, see Fig. 2). However,
the GTG1f female mouse died soon after birth and
the GTG1e female and GTG1c male mice died 3 and
1 months after birth, respectively (Supplementary Fig.
S4A). Moreover, while the surviving female transgenic
mouse (GTG1d) produced one female transgenic
mouse, which safely grew to adulthood, the mother
died during her next pregnancy. Her daughter also
died during her ﬁrst pregnancy. In addition, the sur-
viving male mouse GTG1b only produced male trans-
genic mice when mated with wild-type B6 female
mice because the human G0S2 gene was introduced
into the Y chromosome. Thus, this mouse could not
be used further. Furthermore, the remaining surviving
male mouse, GTG1a, did not produce transgenic
mouse when mated with wild-type B6 female mice.
Thus, we failed to establish a human G0S2-expressing
transgenic strain in this trial. The second trial did not
generate any transgenic mice. However, in the third
trial, of the 22 mice examined by PCR (Fig. 6A) and
western blot analysis (Fig. 6B), we found three
Figure 4. mRNA expression levels of the TAC genes. Individual TAC
genes were subjected to RT–PCR analysis to conﬁrm they are
upregulated in the PBMCs of 50 vasculitis patients (A) but not
in the PBMCs of eight normal volunteers (N). GAPDH was also
analyzed as a loading control. The annealing temperature and
ampliﬁcation cycles for RT–PCR were always 508C and 35
cycles, respectively, with the exception of the reactions
denoted by a (558C, 40 cycles), b (508C, 30 cycles), c (588C,
27 cycles), d (508C, 40 cycles), and e (588C, 30 cycles). The
sequences of the primers used to identify the TAS genes are
presented in Supplementary Table S1.
No. 4] S. Kobayashi et al. 259Table 2. List of microarray identiﬁed TAC genes that show upregulated expression in the PBMCs of vasculitis patients
Gene name Accession number Sequence description
TAC-1 NM_001964 Early growth response 1 (EGR1) gene product
TAC-2 AK025198 Unknown (FLJ21545) ¼ TVAS8
TAC-3 NM_000584 Interleukin 8 (IL8)
TAC-9 NM_001657 Amphiregulin
TAC-14 NM_003596 Tyrosylprotein sulfotransferase 1 (TPST1)
TAC-19 NM_004633 Interleukin 1 receptor, type II (IL1R2)
TAC-28 NM_000715 Complement component 4 binding protein, alpha (C4BPA)
TAC-29 NM_017762 Unknown (FLJ20313) ¼ TVAS9
TAC-30 NM_144590 Unknown (ankyrin repeat domain 22: MGC22805) ¼ TVAS10
TAC-31 BC013734 Prostaglandin-endoperoxide synthase 2
TAC-36 AB044805 6-phosphofructo-2-kinase heart isoform
TAC-37 NM_001511 Chemokine (C-X-C motif) ligand 1 (CXCL1)
TAC-40 NM_015714 G0/G1 switch gene 2 (G0S2)
TAC-43 NM_004545 NADH dehydrogenase (ubiquinone) 1 beta (NDUFB1)
TAC-47 NM_080657 Viperin (cig5)
TAC-54 BC029495 Unknown (MGC:33104) ¼ TVAS11
TAC-55 AF249277 Cervical cancer suppressor-1
TAC-61 BC065737 Unknown (IMAGE:30404477) ¼ TVAS12
TAC-64 NM_000032 Aminolevulinate, delta-, synthase 2 (ALAS2)
TAC-77 NM_000661 Ribosomal protein L9 (RPL9)
TAC-78 NM_004233 CD83 antigen (immunoglobulin superfamily)
TAC-84 X60364 ALAS mRNA for 5-aminolevulinate synthase precursor
TAC-85 AK098605 Unknown (FLJ25739) ¼ TVAS13
TAC-89 NM_004833 Absent in melanoma 2 (AIM2)
TAC-91 NM_001738 Carbonic anhydrase I (CA1)
TAC-102 NM_005143 Haptoglobin (HP)
TAC-106 BQ446275 Hemoglobin delta (HBD)
TAC-115 NM_182522 TAFA4 protein (TAFA4)
TAC-118 L03419 Fc-gamma receptor I B1
TAC-127 NM_007115 Tumor necrosis factor, alpha-induced protein 6 (TNFAIP6)
TAC-141 BX537874 Unknown (DKFZp313P036) ¼ TVAS14
TAC-167 BQ674642 Unknown ¼ TVAS15
TAC-172 AL390162 Unknown (DKFZp761A1916) ¼ TVAS16
TAC-190 NR_001459 Unknown (C14orf62) ¼ TVAS17
TAC-191 NM_002983 Chemokine (C-C motif) ligand 3 (CCL3)
TAC-226 BC031359 Unknown (IMAGE:4778855) ¼ TVAS18
TAC-229 NM_002064 Glutaredoxin (thioltransferase) (GLRX)
TAC-234 NM_000963 Prostaglandin G/H synthase and cyclooxygenase (PTGS2)
TAC-236 NM_001124 Adrenomedullin (ADM)
TAC-237 NM_014320 Heme-binding protein 2 (HEBP2)
TAC-242 AW901958 Unknown ¼ TVAS19
TAC-252 NM_003096 Small nuclear ribonucleoprotein polypeptide G (SNRPG)
TAC-261 NM_014879 G protein-coupled receptor 105 (GPR105)
TAC-266 BC032663 Phorbol-12-myristate-13-acetate-induced protein 1
TAC-269 BC032480 Unknown (IMAGE:5214272) ¼ TVAS20
TAC-273 NM_182619 Secretory protein LOC348174 (LOC348174)
TAC-274 NM_012472 Testis speciﬁc leucine rich repeat protein (TSLRP)
Continued
260 Asculitis-upregulated Genes [Vol. 15,transgenic mice, of which one (GTG3a) produced off-
spring (see Supplementary Fig. S4B). These mice
appear to be healthier than the other transgenic
mice and consequently we have been able to main-
tain this line probably due to lower G0S2 levels than
other transgenic mice. Thus, the exogenous and ubi-
quitous overexpression of human G0S2 seems to
make the transgenic mice unhealthy and inhibits
their production of offspring.
3.5. Human G0S2 expression patterns in transgenic
mice
To examine the expression patterns of exogenous
human G0S2 in various transgenic mouse tissues,
we ﬁrst performed ISH analysis. As shown in some
representative pictures (Fig. 6C), high-level expression
of G0S2 mRNA was detected in various organs and
tissues. The signals in the urinary tubule, gastric
foveola, and esophageal mucosa were distributed in
epithelial clumps (Fig. 6Ci–iii). In contrast, scattered
or diffusely distributed signals were detected in the
cardiac ventricle, gastric smooth muscle, and semini-
ferous tubule (Fig. 6Civ–vi).
Immunohistochemical analysis using the mono-
clonal antibody (#3-1) also detected exogenously
expressed human G0S2 proteins in various organs
and tissues of the transgenic mice. As shown in
some representative pictures (Fig. 6D), the cellular
distribution pattern of these proteins was similar to
that of exogenous G0S2 mRNA (Fig. 6C). In the
kidney, although most urinary tubule epithelia were
Figure 5. Determination of the human blood cells that express
EGR1, HBD, TVAS10, IL1R2, and calgranulin C (Cal C). RT–PCR
was performed by using the multiple-tissue cDNA panel for
human blood fractions (MTC, Clontech). GAPDH was also
ampliﬁed as a loading control. PCR ampliﬁcations were
conducted at 508C over 33 cycles except as indicated at the
right of the panels by # (508C over 30 cycles). Lane 1,
mononuclear cells (B, T cells, and monocytes). Lane 2, resting
CD8þ cells (T-suppressor/cytotoxic cells). Lane 3, resting
CD4þ cells (T-helper/inducer). Lane 4, resting CD14þ cells
(monocytes). Lane 5, resting CD19þ cells (B cells). Lane 6,
activated CD19þ cells (aCD10 þ). Lane 7, activated
mononuclear cells (aMNC). Lane 8, activated CD4þ cells
(aCD8 þ ). Lane 9, activated CD8þ cells. Lane 10, human
placenta, which also includes many blood cells. The latter lane
served as a control.
Table 2. Continued
Gene name Accession number Sequence description
TAC-275 AX721252 Unknown (Patent WO0220754) ¼ TVAS21
TAC-287 NM_032412 Putative nuclear protein (ORF1-FL49)
TAC-295 NM_024850 Butyrophilin-like 8 (BTNL8)
TAC-302 BC005984 Unknown (IMAGE:4247211) ¼ TVAS22
TAC-304 NM_033655 Unknown ¼ TVAS23
TAC-307 BC042517 Unknown (IMAGE:4822953) ¼ TVAS24
TAC-321 AL831953 Unknown (DKFZp667P0410) ¼ TVAS25
TAC-322 AK128746 Unknown (FLJ44672) ¼ TVAS26
TAC-324 AF067801 Unknown (HDCGC21P) ¼ TVAS27
TAC-330 D86962 Unknown (KIAA0207) ¼ TVAS28
TAC-343 NM_004417 Dual speciﬁcity phosphatase 1 (DUSP1)
TAC-353 M64109 Udulin 2
TAC-357 BC053669 Unknown (IMAGE:6146402) ¼ TVAS29
TAC-374 NM_016220 Zinc ﬁnger protein (ZFD25)
TAC-389 NM_001955 Endothelin 1 (EDN1)
TAC-398 NM_020995 Haptoglobin-related protein (HPR)
TAC-401 NM_001161 Nudix (nucleoside diphosphate linked moiety X)-type motif 2 (NUDT2)
TAC-402 AY358224 Unknown (UNQ9368) ¼ TVAS30
The expression levels were examined by RT–PCR (Fig. 2). The underlined genes were subjected to qRT–PCR to determine their generality of
expression in vasculitis patients but not normal volunteers (Fig. 3).
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this protein at high levels; the latter epithelia also
existed in clumps (Fig. 6Di). A similar patchy distri-
bution of strong G0S2 signals was detected in the
foveolar epithelia of the stomach (Fig. 6Dii). In the
lung and heart, there was a scattered distribution of
exogenous G0S2 signals in the alveolar epithelium
and a diffuse distribution in cardiac ventricular
muscle, respectively (Fig. 6Diii and iv).
3.6. Phenotypes of G0S2 transgenic mice
To explore the phenotypes of the G0S2 transgenic
mouse, we ﬁrst subjected various organs of G0S2 trans-
genic mice and wild-type (C57BL/6) mice to histologi-
cal examination. Obvious histopathological ﬁndings
that related directly to vasculitis were not observed.
Notably, microabscess-like panniculitis lesions were
detected in the dermis and subcutaneous fat tissue
(Fig. 7A). Of the eight TG mice examined, such
lesions were detected in three. We also measured the
serum levels of two autoimmunity-related antibodies,
namely, anti-nuclear antibody (ANA) and anti-dsDNA
antibody. We found both were increased in G0S2 TG
mice: the OD490 for ANA in the transgenic mice was
0.359+0.170 [compared with 0.219+0.044 for
wild-type (B6) mice], whereas the OD490 for anti-
dsDNA antibody was 0.294+0.090 (compared with
0.188+0.038 in wild-type mice) (Fig. 7B). However,
these differences did not reach statistical signiﬁcance,
Figure 7. Histological and serological phenotypes of G0S2-TG mice.
(A) Histological phenotype of G0S2-TG mice (GTG1b is shown as
anexample).SectionsofthebackskinofadultG0S2-TGmicewere
stainedwithhematoxylinandeosin.A boxedareaintheleftpanel
is enlarged in the right to show microabscess lesions containing
numerous neutrophils. Original magniﬁcation: left,  100; right,
 400. (B) Serological phenotypes of G0S2-TG mice (GTG1a is
shown as an example). The sera from adult C57BL/6 (open
circle) or G0S2-TG (closed circle) mice were examined for
the levels of ANA and anti-dsDNA antibody. Asterisk and
double asterisks indicate ‘not signiﬁcant’ because P ¼ 0.1011
and P ¼ 0.0526, respectively, as determined by the Mann–
Whitney U-test of differences between G0S2-TG and wild-type
mice. The G0S2 TG mice examined are designated as follows: a
(GTG1a), b (GTG1b), c (GTG1b-F1a), d (GTG1b-F2a), and e
(GTG1b-F1c). The values of individual mice are plotted.
Figure 6. Establishment of G0S2 transgenic mice. (A) An example
of the RT–PCR analyses used to identify G0S2 transgenic mice.
(B) Western blot analysis to identify G0S2 transgenic mice. The
panel for ATG3-F1 and -F2 mice is shown as an example. The
transgenic mouse numbers are underlined. (C) ISH analyses of
G0S2-TG mice. Sections from the kidney (i), stomach (ii,
mucosa; v, smooth muscle), esophagus (iii), heart (iv), and
epididymis (vi) of adult G0S2-TG mice (GTG1b is shown as an
example) were hybridized with the human G0S2 antisense
probe and colored blue by using the alkaline phosphatase
reaction. The nuclei were counterstained with nuclear fast red.
Original magniﬁcation:  200. (D) Immunological detection of
exogenic G0S2 proteins in various organs of G0S2-TG mice
(GTG1b is shown as an example). Sections from the kidney (i),
stomach (ii), lung (iii), and heart (iv) of the adult G0S2-TG
mice were incubated with the mouse monoclonal anti-G0S2
antibody (#3-1) and stained with diaminobenzidine. The
nuclei were counterstained with hematoxylin. Original
magniﬁcation: A and B,  200; C and D,  400.
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wecoulduseforthesemeasurements.Takentogether,it
appears that G0S2 may participate in the pathogenesis
of autoimmune diseases in general, and in particular, it
may be related to inﬂammation.
4. Discussion
In the present study, we report candidate gene
markers for vasculitis that may be useful for diagnos-
ing and understanding the basic pathogenesis of vas-
culitis and other autoimmune diseases such as SLE.
These genes were identiﬁed by stepwise subtraction
and cDNA microarray techniques, which permitted
us to comprehensively isolate the genes that show
augmented mRNA expression in the PBMCs of vascu-
litis patients when compared with normal volunteers.
The vasculitis-speciﬁc upregulation of these genes was
validated with northern blot and/or RT–PCR analyses
(Figs 3 and 4, Tables 1 and 2). We then showed by
RT–PCR analysis that EGR1, G0S2, HBD, TVAS10,
IL1R2, Amphiregulin, and calgranulin C are frequently
upregulated in the PBMCs of vasculitis patients
(Fig. 1 and Supplementary Fig. S1). MTC analysis
revealed that in normal PBMCs, these genes are
expressed primarily by monocytes and/or activated
CD4þ cells (Fig. 5). We also showed previously using
different primers and PCR conditions that G0S2 is pre-
dominantly expressed by monocytes.
5 These results
suggest that monocytes, including macrophages,
express these vasculitis-upregulated genes and thus
may play a role in the pathogenesis of vasculitis.
We noticed that several putative vasculitis-upregu-
lated genes also show upregulated expression in
other autoimmune diseases, namely, SLE and RA
(Table 3). Of these, EGR1 is particularly interesting
as the degree to which it is upregulated in most vascu-
litis patients is remarkable (Fig. 1A). EGR1 is induced
by a variety of cellular stresses, including hypoxia,
and may function as a master switch that triggers
the expression of numerous key inﬂammatory
mediators. In particular, EGR1 induces a number of
gene products that have been linked to cellular per-
turbation, especially in the vasculature. Moreover,
many of these genes are often induced in the PBMCs
of patients afﬂicted with a variety of autoimmune dis-
eases. For example, we showed previously that EGR1 is
markedly upregulated in the PBMCs of SLE patients.
4 It
also plays a critical role in promoting cellular differen-
tiation along a macrophage lineage.
10 Nonetheless,
EGR1-null mice are viable and develop and grow nor-
mally.
19 Rigorous analyses will be needed to deter-
mine whether the upregulation of EGR1 mRNA in
many vasculitis patients is pathogenically signiﬁcant
or merely an associated phenomenon.
G0S2 also displayed enhanced expression in many
vasculitis patients (Fig. 1B). G0S2 was ﬁrst identiﬁed
as one of the G0/G1 switch (G0S) genes that are dif-
ferentially expressed in lymphocytes during their
lectin-induced switch from the G0 to the G1 phases
of the cell cycle.
20 G0S2 is one of the genes that is
upregulated during normal implantation but its
expression is signiﬁcantly lower in women with endo-
metriosis that is associated with pelvic pain and
infertility with implantation failure.
21 In a replicative
senescence model employing human dermal ﬁbro-
blasts (HDF), G0S2 expression was upregulated in
old HDF cells, which suggests that it participates in
senescence.
22 Microarray and qRT–PCR analyses of
Table 3. List of the TAC/TAS genes that also show upregulated expression in PBMCs from SLE and RA patients
Name Vasculitis SLE RA Sequence description
TAC-1 42.0 44.7 nc Early growth response 1 (EGR1)
TAC-2 41.7 24.1 nc Unknown (FLJ21545) ¼ TVAS8
TAC-3 29.7 23.2 2.4 Interleukin 8 (IL8)
TAC-9 12.3 12.3 27.4 Amphiregulin
TAC-13 9.7 11.3 1.8 CD69 antigen (early T-cell activation antigen)
TAC-14 9.4 7.2 3.9 Tyrosylprotein sulfotransferase 1 (TPST1)
TAC-19 9.1 5.3 9.4 Interleukin 1 receptor, type II (IL1R2)
TAC-20 8.8 18.0 1.4 Similar to interferon alpha-inducible protein 27
TAC-34 6.9 11.5 2.4 Sin3-associated polypeptide, 30kDa (SAP30)
TAC-37 6.8 3.9 2.4 Chemokine (C-X-C motif) ligand 1 (CXCL1)
TAC-40 6.7 14.8 4.0 G0/G1 switch gene 2 (G0S2)
TAC-47 6.4 20.7 nc Viperin (cig5)
TAC-51 6.2 10.7 4.4 Nuclear factor of kappa B (NFkB)
TAC-78 5.5 11.4 1.7 CD83 antigen (immunoglobulin superfamily)
The numbers represent fold change compared with normal volunteers; nc, no conspicuous change between RA and control.
No. 4] S. Kobayashi et al. 263PBMCs from psoriasis patients suffering from severe
generalized disease also revealed the upregulation of
G0S2.
13 Moreover, we showed previously that G0S2
mRNA levels are markedly increased in the PBMCs
from patients with the autoimmune diseases SLE
4
and RA.
5 G0S2 is a putative target gene of peroxi-
some-proliferator-activated receptor (PPAR) alpha,
which belongs to a group of transcription factors
that are involved in numerous processes, including
lipid metabolism and adipogenesis. Moreover, it was
shown that G0S2 is upregulated after PPARd activation
and that it may be involved in the PPARd-mediated
mitigation of cardiac ﬁbroblast proliferation.
23
We here generated G0S2-TG mice that ubiquitously
overexpress G0S2 proteins (Fig. 6). We showed that
these mice are unhealthy as they do not produce
many offspring (Fig. 2) and frequently display for-
mations of microabscess-like panniculitis lesions in
the dermis and subcutaneous fat tissue (Fig. 7A).
The development of these microabscess-like pannicu-
litis lesions may reﬂect the dysregulation of the
murine immune system in these mice. Supporting
this is that some of the G0S2-TG mice had augmented
levels of immunodeﬁciency-related anti-nuclear and
anti-dsDNA antibodies in their sera (Fig. 7B), although
these phenotypes are related not to vasculitis but to
SLE. It should be noted, however, that these serum
differences did not achieve statistical signiﬁcance,
largely because of the shortage of G0S2-TG mice. It
will be necessary to study larger numbers of G0S2-
TG mice to conﬁrm this association between G0S2
overexpression and the development of autoimmune
features. Should this association be conﬁrmed, the
high-quality polyclonal and monoclonal anti-G0S2
antibodies that we produced may be useful as tools
(perhaps in enzyme-linked EIA) for diagnosing not
just vasculitis but also other autoimmune diseases.
We performed this study on a highly heterogeneous
cohort of patients, including those with systemic vas-
culitis. All of these diseases share the inﬂammatory
involvement of blood vessels. However, their target
organs, pathogenic mechanisms, clinical ﬁndings,
and outcomes are quite different. Moreover, although
the disease activity status in these patients was het-
erogeneous and some were receiving corticosteroid
or immunosuppressive therapy, these factors
were ignored in our patient recruitment protocol.
Nonetheless, despite these marked heterogeneous
features of our patient population, we could isolate
putative common genes that are upregulated, which
was our original goal. We are currently performing
in parallel the expression proﬁling of the genes that
are up- or downregulated in each individual disease
and analyzing these proﬁles in terms of the symp-
toms, disease activity status, and clinical treatment
of the patients. However, the results obtained from
such studies are highly complex, which has hampered
the identiﬁcation of candidate gene markers that can
be used for diagnosis.
Taken together, we conclude that the putative gene
markers we identiﬁed here, in particular EGR1 and
G0S2, may be useful for diagnosing not only vasculitis
but also other autoimmune diseases, perhaps by
qRT–PCR and antibody-based methods. Other, as
yet uncharacterized, genes that we detected as being
upregulated in vasculitis may also be useful candidate
gene markers and thus are worth further detailed
analysis. In particular, the identiﬁcation of the func-
tions of these genes may reveal the hitherto
unknown mechanism(s) that underlie the pathogen-
esis of vasculitis. This in turn may shed light on thera-
peutic avenues for treating vasculitis.
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